lncRNA PCAT19 negatively regulates p53 in non‑small cell lung cancer

Zhang,Xiaokai; Wang,Qiwen; Xu,Yajuan; Wang,Bao; Jia,Chunyi; Wang,Lei; Sun,Hongmei; Zhao,Hui; Wang,Zhe; Zou,Qinguang; Sun,Shaolin; Zhang,Lixin

doi:10.3892/ol.2019.11041

lncRNA PCAT19 negatively regulates p53 in non‑small cell lung cancer

Authors:
- Xiaokai Zhang
- Qiwen Wang
- Yajuan Xu
- Bao Wang
- Chunyi Jia
- Lei Wang
- Hongmei Sun
- Hui Zhao
- Zhe Wang
- Qinguang Zou
- Shaolin Sun
- Lixin Zhang
View Affiliations

Affiliations: Department of Thoracic Oncosurgery, Jilin Province Tumor Hospital, Chaoyang, Changchun, Jilin 130012, P.R. China, Department of Oral and Maxillofacial Surgery, Jilin Province Tumor Hospital, Chaoyang, Changchun, Jilin 130012, P.R. China
Published online on: November 4, 2019 https://doi.org/10.3892/ol.2019.11041
Pages: 6795-6800

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to investigate the influence of long non‑coding (lnc)RNA prostate cancer associated transcript (PCAT)19 on the progression of non‑small cell lung cancer (NSCLC). It was determined that PCAT19 expression was upregulated in NSCLC tissues and also predicted poor patient survival rate. Additionally, p53 expression was downregulated in NSCLC specimens, which was negatively correlated with PCAT19 expression. Moreover, in H1993 NSCLC cells, silencing of the PCAT19 gene led to an increase in the expression of p53, whilst conversely, its overexpression led to p53 downregulation. PCAT19 silencing was associated with the decreased proliferation rate of NSCLC cells, while PCAT19 overexpression led to increased proliferation. In addition, p53 overexpression, achieved through the transfection of a p53 expression vector, attenuated the effects of PCAT19 overexpression on cell proliferation. In conclusion, the present study demonstrated that PCAT19 negatively regulates the p53 tumor‑suppression pathway, promoting cancer cell proliferation in patients with NSCLC.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
2	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
3	Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, Stein KD, Alteri R and Jemal A: Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 66:271–289. 2016. View Article : Google Scholar : PubMed/NCBI
4	Herbst RS, Morgensztern D and Boshoff C: The biology and management of non-small cell lung cancer. Nature. 553:446–454. 2018. View Article : Google Scholar : PubMed/NCBI
5	Postmus PE, Kerr KM, Oudkerk M, Senan S, Waller DA, Vansteenkiste J, Escriu C and Peters S; ESMO Guidelines Committee, : Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 28 (Suppl_4):iv1–iv21. 2017. View Article : Google Scholar : PubMed/NCBI
6	Labuschagne CF, Zani F and Vousden KH: Control of metabolism by p53-cancer and beyond. Biochim Biophys Acta Rev Cancer. 1870:32–42. 2018. View Article : Google Scholar : PubMed/NCBI
7	Evan GI and Vousden KH: Proliferation, cell cycle and apoptosis in cancer. Nature. 411:342–348. 2001. View Article : Google Scholar : PubMed/NCBI
8	Joerger AC and Fersht AR: The p53 pathway: Origins, inactivation in cancer, and emerging therapeutic approaches. Annu Rev Biochem. 85:375–404. 2016. View Article : Google Scholar : PubMed/NCBI
9	Huarte M: The emerging role of lncRNAs in cancer. Nat Med. 21:1253–1261. 2015. View Article : Google Scholar : PubMed/NCBI
10	Engreitz JM, Haines JE, Perez EM, Munson G, Chen J, Kane M, McDonel PE, Guttman M and Lander ES: Local regulation of gene expression by lncRNA promoters, transcription and splicing. Nature. 539:452–455. 2016. View Article : Google Scholar : PubMed/NCBI
11	Hua JT, Ahmed M, Guo H, Zhang Y, Chen S, Soares F, Lu J, Zhou S, Wang M, Li H, et al: Risk SNP-mediated promoter-enhancer switching drives prostate cancer through lncRNA PCAT19. Cell. 174:564–575.e18. 2018. View Article : Google Scholar : PubMed/NCBI
12	Xu S, Guo J and Zhang W: lncRNA PCAT19 promotes the proliferation of laryngocarcinoma cells via modulation of the miR-182/PDK4 axis. J Cell Biochem. 120:12810–12821. 2019. View Article : Google Scholar : PubMed/NCBI
13	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
14	Wu Y, Zhang L, Wang Y, Li H, Ren X, Wei F, Yu W, Wang X, Zhang L, Yu J and Hao X: Long noncoding RNA HOTAIR involvement in cancer. Tumour Biol. 35:9531–9538. 2014. View Article : Google Scholar : PubMed/NCBI
15	Li Z, Shen J, Chan MT and Wu WK: TUG1: A pivotal oncogenic long non-coding RNA of human cancers. Cell Prolif. 49:471–475. 2016. View Article : Google Scholar : PubMed/NCBI
16	Li J, Zhang M, An G and Ma Q: LncRNA TUG1 acts as a tumor suppressor in human glioma by promoting cell apoptosis. Exp Biol Med (Maywood). 241:644–649. 2016. View Article : Google Scholar : PubMed/NCBI
17	Canadian Task Force on Preventive Health Care, . Recommendations on screening for lung cancer. CMAJ. 188:425–432. 2016. View Article : Google Scholar : PubMed/NCBI
18	Wei GH and Wang X: lncRNA MEG3 inhibit proliferation and metastasis of gastric cancer via p53 signaling pathway. Eur Rev Med Pharmacol Sci. 21:3850–3856. 2017.PubMed/NCBI
19	Handa H, Hashimoto A, Hashimoto S, Sugino H, Oikawa T and Sabe H: Epithelial-specific histone modification of the miR-96/182 locus targeting AMAP1 mRNA predisposes p53 to suppress cell invasion in epithelial cells. Cell Commun Signal. 16:942018. View Article : Google Scholar : PubMed/NCBI